Verdiva Bio
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
$410M Series A ·
Led by Forbion Capital Partners · Source: markets.financialcontent
Funding history ↓Signals
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $410M | markets.financialcontent |
Timeline
- Website created
Founders and team
JH
Jane Hughes FounderKF
Khurem Farooq FounderLinkedIn · also Aiolos BioTM
Tapan Maniar FounderAT
Ashley Taylor Chief Technology Officer- JMJason Mallory Senior Vice President of Clinical Development
ME
Mohamed Eid Chief Medical OfficerSM
Steve Marso Chief Medical Officer
Investors
FForbion Capital Partnerslead investor
GGeneral Atlanticlead investor
LLilly Asia Ventures
LLogos Capital
LLYFE Capital
OOrbiMed
RRA Capital Management
Companies like Verdiva Bio
NNoema PharmaSeries B+ · Nov 2025
HHelicoreSeries A · Jan 2025
RReRx
NNourish$100M Series B+ · May 2026
NNeuShen Therapeutics$80M Series B+ · Sep 2026
RRevier Therapeutics$6.95M Seed · Aug 2026
Other companies backed by Forbion Capital Partners
OOMass Therapeutics$310M Series B+ · Oct 2026
KKynexis$112.57M Series A · Aug 2026
RRQ Bio$115M Series A · Jun 2026
CCellCentric$220M Series B+ · May 2026
TTropic Biosciences$105M Series B+ · Mar 2026
SSidera Bio$109.99M Series A · Nov 2025
Forbion Capital Partners portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/verdiva-bio (get a free API key).